Applied Genetic Technologies Corporation
AGTC · NASDAQ
6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.12 | -0.00 | 0.37 |
| FCF Yield | -195.43% | -41.41% | -36.63% | -35.38% |
| EV / EBITDA | -0.17 | -0.83 | -1.90 | -9.31 |
| Quality | ||||
| ROIC | -132.28% | -50.99% | -53.16% | -5.46% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.95 | 0.88 | 0.91 | 11.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -49.02% | -77.11% | -53.37% | 1.84% |
| Free Cash Flow Growth | -27.77% | -23.86% | -80.15% | 28.67% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | 1.41 | 0.59 | 6.14 |
| Interest Coverage | -24.78 | -38.81 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |